Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Molecular Imaging Enables Earlier, Individualized Treatment of Thyroid Cancer

By HospiMedica International staff writers
Posted on 27 Jan 2009
In a study to determine the diagnostic benefits of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to effectively distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery.

Researchers from the University of Erlangen-Nuremberg (Germany) reported in an article in the January 2009 issue of The Journal of Nuclear Medicine (JNM) on the findings of a study using a hybrid single photon emission computed tomography-computed tomography (SPECT-CT) system to determine and locate the metastasis of cancer cells to nearby lymph nodes.

According to the researchers, the demonstration or exclusion of cancer spread in regional lymph nodes plays a major role in treating the disease since all patients with lymph node metastases are considered to be at high risk for recurrence.

Currently, patients with differentiated thyroid carcinoma (DTC) who have had their thyroid removed are treated with radioactive iodine, which effectively hones in on and kills any remaining cancerous thyroid cells. More...
Because one of the functions of the thyroid gland is to absorb iodine from the blood, radioiodine is taken up by any thyroid tissue not removed by surgery, including cancerous cells spreading to other body areas, such as lymph nodes. In addition to emitting electrons that destroy the tissue harboring the radionuclide, radioactive iodine emits photons suitable for imaging.

"Normal thyroid tissue as well as residual cancer cells concentrate radioiodine. Performed after ingestion of radioiodine, SPECT-CT provides three-dimensional images of the distribution of the radionuclide in the human body and is therefore used for staging this type of cancer,” said Torsten Kuwert, M.D., coauthor of the study. "Incorporated at first treatment, SPECT-CT allows us to better stratify patients into treatment groups.”

In the study, 57 patients received radioiodine therapy. After that, a SPECT-CT camera was rotated around the patients at a variety of angles to capture where the radioactivity was occurring. SPECT imaging can locate cells in the body that are not behaving normally, but does not provide the detailed, X-ray-like images that CT imaging can. The hybrid camera, however, is able to reveal both the malignant cell activity and the exact anatomical location.

"With SPECT-CT imaging, we were able to determine tumor spread much earlier than before,” said Daniela Schmidt, M.D., another coauthor of the article. "Earlier detection will lead to earlier individualized treatment of this potentially deadly cancer.”

The researchers also reported that this information led to a revision of the original diagnosis in 35% of the study participants. The images reclassified as benign 6 of 11 lesions that had been considered lymph node metastases and 11 of 15 lesions considered to be indeterminate.

"Our data suggest that SPECT-CT should be used as a routine procedure in DTC patients at the first radioiodine treatment,” said Dr. Kuwert. "By upstaging or downstaging disease, this hybrid imaging tool may alter the management of more than one-third of patients with the disease.”

According to the American Cancer Society, DTC is the most common form of thyroid cancer and one of the success stories in the war on cancer. Since the advent of radioiodine therapy, it has been considered one of the more curable of cancers.

Related Links:

University of Erlangen-Nuremberg




Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Examination & Procedure Light
Vega 80
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.